{"id":"comparator-carvedilol","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Dizziness"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Bradycardia"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5","effect":"Hyperglycemia"},{"rate":"5-10","effect":"Erectile dysfunction"},{"rate":"<5","effect":"Bronchospasm"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Comparator: carvedilol","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:21:39.126275+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:21:45.426974+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Comparator: carvedilol","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:21:46.235120+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Adrenergic receptor alpha-1 antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:21:46.873790+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201167/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:21:46.775510+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carvedilol blocks beta-1, beta-2, and alpha-1 adrenergic receptors, reducing sympathetic nervous system activity on the heart and blood vessels. This dual action decreases heart rate and contractility while causing vasodilation, making it effective for managing hypertension and heart failure by reducing cardiac oxygen demand and improving hemodynamics.","oneSentence":"Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:05.697Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:21:49.061243+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Left ventricular dysfunction following myocardial infarction"},{"name":"Angina pectoris"}]},"trialDetails":[{"nctId":"NCT07322237","phase":"PHASE4","title":"DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2026-01-01","conditions":"Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors","enrollment":400},{"nctId":"NCT06431919","phase":"NA","title":"Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2025-06-10","conditions":"Decompensated Cirrhosis, Cirrhotic Cardiomyopathy, Cirrhosis, Liver","enrollment":260},{"nctId":"NCT00496834","phase":"PHASE4","title":"LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02-01","conditions":"Hypertension","enrollment":201},{"nctId":"NCT05580510","phase":"PHASE2, PHASE3","title":"\" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD \"","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2023-02-06","conditions":"Congenital Heart Disease, Heart Failure, Heart Failure With Reduced Ejection Fraction","enrollment":160},{"nctId":"NCT00108082","phase":"PHASE3","title":"The CLEVER Study - Coreg And Left Ventricular Mass Regression","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01","conditions":"Hypertrophy, Left Ventricular","enrollment":287},{"nctId":"NCT01221792","phase":"PHASE2","title":"Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)","status":"UNKNOWN","sponsor":"Columbia Northwest Pharmaceuticals","startDate":"2010-10","conditions":"Post-Traumatic Stress Disorder","enrollment":80},{"nctId":"NCT00864149","phase":"PHASE1","title":"A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Non-fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-10","conditions":"Healthy","enrollment":36},{"nctId":"NCT00864435","phase":"PHASE1","title":"A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-10","conditions":"Healthy","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1201167"},"_approvalHistory":[],"publicationCount":1590,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Comparator: carvedilol","genericName":"Comparator: carvedilol","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload. Used for Hypertension, Heart failure with reduced ejection fraction, Left ventricular dysfunction following myocardial infarction.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:21:49.061243+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}